Cystic fibrosis (CF) is a genetic metabolic disease. Currently it cannot be cured, but intensive research means there are now effective treatments available. The outlook in terms of life expectancy is now much better. The most important thing to note is that only close collaboration with a CF treatment team can ensure that they can decide on the best available therapy for their patients.
Cystic fibrosis (CF) is a genetic metabolic disease caused by a gene defect, a mutation of the cystic fibrosis gene: the CFTR gene.
This mutation leads to the production of thick mucus in many organs of the body. For instance, it “blocks” the airways, leading to inflammation, infection and lung damage. The thick mucus is also what gives its names to an alternative term for cystic fibrosis - mucoviscidosis - from the Latin for viscous and mucus.
The CFTR gene leads to the expression of the “Cystic Fibrosis Transmembrane Conductance Regulator”. This kind of regulator is a protein is located on the surface of the cells of many of the organs in the body and acts like a channel. The mutation in the CFTR gene – which usually ensures that salt and water can move in and out of the cell – causes a defective channel and therefore a dysfunction in the salt and water balance. This means that too little water moves to the mucus coating the cells, making it thick.
Cystic fibrosis can trigger symptoms in any organ in which the CFTR channel protein acts. The symptoms may also vary from one patient to another. The airways and pancreas are especially often affected.
The thick mucus in the pancreas blocks pancreatic enzymes from reaching the small intestine. This leads to:
The genetic defect causing salt-water inbalance in the cell means that patients have very salty sweat. It is therefore important to keep a close eye on electrolyte intake.
While there is no cure for cystic fibrosis, it can now be effectively treated thanks to therapies that have been continuously developed over the last few decades. Close collaboration with patients and their doctors, physiotherapists and other practitioners is the key to successful treatment.
There are several components involved in the treatment of cystic fibrosis. As well as drug therapy, treatment also involves inhalation therapy with hypertonic saline solution, respiratory therapy and physiotherapy, nutritional therapy and sport therapy. The goals of the therapy can be roughly divided into symptomatic and a more causal treatment.
Symptomatic treatment has underpinned the treatment of cystic fibrosis for decades. It is designed to reduce symptoms, slow down disease progression and improve quality of life.
Inhalation therapy is the cornerstone of symptomatic treatment for cystic fibrosis. The disease primarily affects the airways, where it prevents the thick mucus from transporting away pathogens, promotes their growth and so increases the risk of infections. Suitable inhalation devices deliver active ingredients directly to the target organs – the lungs. Inhalation therapy has a two-pronged approach:
Further information on inhalation for cystic fibrosis is available here.
Respiratory therapy/physiotherapy is a more intensive and varied component in the treatment of cystic fibrosis. It involves various exercises to clear the mucus, exercises to prevent hyperinflation of the lungs and respiratory therapy equipment, such as PEP systems.
Over the past decades, a combination of respiratory therapy/physiotherapy and inhalation therapy has proven effective and is generally recommended.
The website of the organisation Mukoviszidose e.V. has a practical search function for addresses of physiotherapists for cystic fibrosis.
CFTR modulators are a group of drugs that have been especially developed for the treatment of cystic fibrosis. They therapeutically target the cause of the cystic fibrosis, the faulty CFTR channel. There are various types of CFTR modulators:
The introduction of CFTR modulators, especially in triple combination (consisting of two correctors and one potentiator) has changed the treatment of cystic fibrosis.
Inhalation therapy for cystic fibrosis takes time and patients therefore justifiably often ask this question. Experts agree that, even if a patient is taking CFTR modulators, they should usually continue with the inhalation therapy, especially if they have irreversible lung damage, frequent exacerbations and chronic infection. This applies to the inhalation of hypertonic saline solution, but also especially to the inhalation of antibiotics.
As described, the treatment of cystic fibrosis is complex, includes various components and ultimately varies from one person to another. In particular, with the triple combination of CFTR modulators has changed cystic fibrosis treatment even further. For patients to enjoy the best possible benefit, treatment should continue in close consultation with the team of healthcare professionals at the CF centre. This applies especially to inhalation therapy, which maintains to be an important pillar in the treatment of cystic fibrosis.
Other helpful information on the subject:
https://www.pari.com/de/blog/inhalation-triple-cftr-modulator-interview/
https://www.pari.com/de/blog/inhalieren-trotz-triple-cftr-modulatoren/
Exercise with cystic fibrosis: https://www.muko.info/mitwirken/arbeitskreise-und-arbeitsgemeinschaften/ak-sport/sport-bei-mukoviszidose
Diet with cystic fibrosis: https://www.muko.info/mitwirken/arbeitskreise-und-arbeitsgemeinschaften/ak-ernaehrung
Physiotherapy with cystic fibrosis: https://www.muko.info/mitwirken/arbeitskreise-und-arbeitsgemeinschaften/ak-physiotherapie
Contact us
Any questions? You can reach our service center at this number:
+49 8151 279-5220
© 2024 PARI GmbH Spezialisten für effektive Inhalation